Health breakthroughs and money matters, in plain words

Home » Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices

Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices

By

–

Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices

For a family handling a rectal cancer diagnosis, the first questions are usually about surgery, radiation and chemotherapy. A new FDA decision changes the conversation for one group of patients. On October 19, 2026, the agency granted accelerated approval to dostarlimab (Jemperli), a PD-1 inhibitor, for adults with stage II or III locally advanced rectal cancer whose tumors are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). It approved the drug four months ahead of its goal date, and the label may let some patients avoid surgery, radiation and further systemic therapy.

The Marker Behind the Decision

Mismatch repair is the cell’s spell-check for DNA. When it fails, the tumor is called MSI-H or dMMR, a status that shapes both prognosis and eligibility for immune checkpoint inhibitors. That is why testing matters: the approval applies only to patients whose tumors carry the marker, as determined by an FDA-authorized test.

Researchers in Hebei, China, recently described how that testing is done in a dataset of 77 patients with second primary colorectal cancers. Pathologists stain thin tumor sections for four proteins, MLH1, MSH2, MSH6 and PMS2. Internal controls must stain clearly before a slide counts, and total absence of staining in the tumor means the protein is lost. Unclear cases get a second pathologist. When staining cannot settle the question, PCR assays look at five markers (BAT-25, BAT-26, NR-21, NR-24 and NR-27), and instability at two or more means MSI-H. In that group, 16 patients, or 20.8 percent, were MSI-H or dMMR.

What the Trial Found

The approval rests on AZUR-1, a phase 2, multicenter, single-arm, open-label trial (NCT05723562) of 154 previously untreated patients. They received dostarlimab 500 mg intravenously every three weeks for up to nine cycles. Response was checked by endoscopy, rectal MRI and CT scans at week 6, week 12 and about three weeks after treatment ended. Patients with a clinical complete response entered non-operative management, with scans and exams every four months for two years and then every six months.

By independent central review, the objective response rate was 79 percent. Among 116 evaluable patients, 47 percent had a sustained clinical complete response lasting at least 12 months. At a median follow-up of 26.3 months, 110 of the 154 patients, or 71 percent, had received dostarlimab alone with no further treatment and no progression. Another 26 had surgery, 13 had more systemic therapy or radiation, one progressed without more treatment, and four withdrew or were lost to follow-up.

Fifteen patients had surgery after dostarlimab because imaging hinted at an incomplete response, and 12 of them showed a pathological complete response. At the data cutoff, 38 more patients had a clinical complete response but less than 12 months of follow-up, and 44 had a near-complete response. None of the patients with a complete or near-complete response had disease progression. Patients who did not respond, or whose cancer returned, were evaluated for standard care at the investigators’ discretion.

A Second, Smaller Study

The FDA also reviewed an investigator-led trial (NCT04165772) of 50 previously untreated patients. Sustained clinical complete response at 12 months reached 93 percent and the objective response rate was 100 percent. No one received chemoradiation or rectal cancer surgery. Of 27 patients followed at least three years, one had a local recurrence treated with lymphadenectomy, one withdrew and one died of causes unrelated to the disease.

The label carries warnings for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic stem cell transplantation and embryo-fetal toxicity. Anyone facing this diagnosis should ask their oncologist about molecular testing, since the answer decides which treatments are on the table.

Sources

Photo: Chris j wood (CC BY-SA 4.0)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News